Investigational therapies for psoriasis - 29/08/11
Doi : 10.1016/S0190-9622(03)01147-2
Abstract |
As the pathogenesis of psoriasis is better understood, specific targeted therapies are being developed. In addition to alefacept, etanercept, efaluzimab, and infliximab, discussed in separate articles in this issue, numerous other investigational therapies are currently in clinical trials, some of which will likely be approved in the future. We review the most promising of these therapies and their mechanisms of action.
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: None. Disclosure: Dr Cather and Dr Abramovits have participated in clinical trials funded by IDEC-114, Amgen, Biogen, Centocor, Fujisawa, Novartis, Ligand, Allergan, Protein Design Labs, Genentech, and Corixa. Dr Cather is a consultant and a speaker for Ligand, Biogen, Genentech, and Allergan. Dr Abramovits is a consultant for Fuijisawa, Astralis, and Novartis. Dr J. C. Cather has no conflicts of interest. |
© 2003
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 49 - N° 2S
P. 133-138 - août 2003 Retour au numéro
Article précédent
- Evaluation and management of psoriatic arthritis: the role of biologic therapy
- Eric M Ruderman
- Integrating biologic therapies into a dermatology practice: practical and economic considerations
- Mark Craze, Melodie Young
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?